欢迎使用我们的服务！
限时优惠，立即购买享受折扣
24小时客服在线，随时为您服务
优质产品，值得信赖

印度仿制药专卖店
登录
顶 置

文章列表

BMS Targets Community Setting With Zenbexus, Its First Approved CELMoD

2026-08-15
First-in-class house dust mite allergy treatment now available in Scotland

2026-08-15
New leadership team appointments

2026-08-15
Frank, in-depth discussion as Belgium and WHO map ahead priorities for collaboration

2026-08-14
AGI celebrates Great Place to Work® certification for 2026–2027

2026-08-14
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

2026-08-14
Strengthening public health across Lebanon with EIB Global

2026-08-14
First-in-class house dust mite allergy treatment now available in Scotland

2026-08-14
Frank, in-depth discussion as Belgium and WHO map ahead priorities for collaboration

2026-08-13
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026

2026-08-13
Attruby Poised To Lead First-Line ATTR-CM, BridgeBio Says

2026-08-13
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

2026-08-13